Provided are methods for treating a disorder characterized by elevated blood glucose levels in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a hyperimmunized egg product obtained from an egg-producing animal, wherein the hyperimmunized egg product comprises a therapeutically effective amount of one or more IgY antibodies to an extracellular glucose binding domain of a sodium-glucose co-transporter SGLT. Also provided are hyperimmunized eggs and egg products produced by an animal that has been hyperimmunized with an antigen that contains an extracellular glucose binding domain of a sodium-glucose co-transporter SGLT or fraction thereof, and use of the hyperimmunized eggs or hyperimmunized egg products to reduce blood glucose levels in a subject, such as to treat type 2 diabetes. Methods or preparing the hyperimmunized eggs and hyperimmunized egg products are also provided.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 39/00 - Medicinal preparations containing antigens or antibodies
A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
2.
COMBINATIONS OF VITAMIN D3, NIACINAMIDE AND LIPOIC ACID FOR USE IN THE MAINTENANCE OF HEALTHY BLOOD GLUCOSE LEVELS
Provided is a health supplement product that can be administered to subjects with pre-diabetes and type 2 diabetes, the product comprising a fixed dose combination of vitamin D3, niacinamide (which is a form of vitamin B3), and lipoic acid (which is an antioxidant) that improves glucose uptake by muscle cells. The compositions address critical molecular steps in muscle glucose uptake and metabolism to result in blood glucose and A1C lowering. In vitro and in vivo data support the use of the combination for glucose control in subjects having prediabetes and as a supplement to other therapeutic treatments in type 2 diabetics.
Provided are methods for treating a disorder characterized by elevated blood glucose levels in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a hyperimmunized egg product obtained from an egg-producing animal, wherein the hyperimmunized egg product comprises a therapeutically effective amount of one or more IgY antibodies to an extracellular glucose binding domain of a sodium-glucose co-transporter SGLT. Also provided are hyperimmunized eggs and egg products produced by an animal that has been hyperimmunized with an antigen that contains an extracellular glucose binding domain of a sodium-glucose co-transporter SGLT or fraction thereof, and use of the hyperimmunized eggs or hyperimmunized egg products to reduce blood glucose levels in a subject, such as to treat type 2 diabetes. Methods or preparing the hyperimmunized eggs and hyperimmunized egg products are also provided.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C07K 16/18 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans
A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
4.
Hyperimmunized egg product for treatment or prevention of coronavirus infection
In one aspect, the present disclosure is directed to a method for preventing or treating a coronavirus infection in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a hyperimmunized egg product obtained from an egg-producing animal, thereby preventing or treating coronavirus infection in the subject, wherein the hyperimmunized egg product comprises a therapeutically effective amount of one or more antibodies to the coronavirus. The present disclosure is also directed to hyperimmunized eggs and egg products produced by an animal that has been hyperimmunized with an antigen selected from i) a spike (S) protein, an S1 subunit protein, an S2 subunit protein, a receptor binding domain (RBD), and an immunogenic fragment thereof; ii) a nucleocapsid (N) protein, and an immunogenic fragment thereof; iii) a human ACE2 receptor protein, and an immunogenic fragment thereof; and iv) a human coronavirus selected from the group consisting of SARS-CoV, MERS-CoV, SARS-CoV-2, HCoV-HKU1, HCoV-NL63, HCoV-OC43 and HCoV-229E. Methods of preparing the hyperimmunized eggs and egg products are also disclosed.
In one aspect, the present disclosure is directed to a method for preventing or treating a coronavirus infection in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a hyperimmunized egg product obtained from an egg-producing animal, thereby preventing or treating coronavirus infection in the subject, wherein the hyperimmunized egg product comprises a therapeutically effective amount of one or more antibodies to the coronavirus. The present disclosure is also directed to hyperimmunized eggs and egg products produced by an animal that has been hyperimmunized with an antigen selected from i) a spike (S) protein, an S1 subunit protein, an S2 subunit protein, a receptor binding domain (RBD), and an immunogenic fragment thereof; ii) a nucleocapsid (N) protein, and an immunogenic fragment thereof; iii) a human ACE2 receptor protein, and an immunogenic fragment thereof; and iv) a human coronavirus selected from the group consisting of SARS-CoV, MERS-CoV, SARS-CoV-2, HCoV-HKU1, HCoV-NL63, HCoV-OC43 and HCoV-229E. Methods of preparing the hyperimmunized eggs and egg products are also disclosed.
The present invention provides a protein drug consisting of chicken IgY antibodies against Sars CoV-2 spike protein receptor binding domain (RBD) which is used prophylactically and/or therapeutically against COVID-19 infections.
patents
